Redefining the Limits: How Tumor-Informed Ultrasensitivity is Transforming the Landscape of Liquid Biopsy & Cancer Monitoring
- Detection at 1-3 PPM: Leveraging tumor-informed ultrasensitivity to detect trace molecular signals previously beyond the reach of standard liquid biopsy
- Enhanced Clinical Endpoints: Identifying therapy responders faster than traditional imaging through validated MRD monitoring across multiple cancer indications
- Accelerated Drug Development: Streamlining trial enrichment to facilitate the use of MRD as a surrogate endpoint